BioCryst Pharmaceuticals Inc Cash Flow Conversion Efficiency
BioCryst Pharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, BioCryst Pharmaceuticals Inc (BCRX) has a cash flow conversion efficiency ratio of 0.112x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-62.14 Million) by net assets ($-553.84 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of BioCryst Pharmaceuticals Inc (1994–2025)
Cash flow conversion efficiency of BioCryst Pharmaceuticals Inc from 1994 to 2025. This chart illustrates how BioCryst Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View BioCryst Pharmaceuticals Inc share price for real-time trading data and today's change.
BioCryst Pharmaceuticals Inc Cash Flow Conversion Ratio Explained
BioCryst Pharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
BioCryst Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BioCryst Pharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see BCRX stock market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Endeavour Silver Corp.
TO:EDR
|
0.057x |
|
Mednax Inc
NYSE:MD
|
0.142x |
|
V2X Inc
NYSE:VVX
|
0.037x |
|
Empresas Cablevisión S.A.B. de C.V
MX:CABLECPO
|
0.177x |
|
Foran Energy Group Co Ltd
SHE:002911
|
-0.014x |
|
Electric Connector Technology Co Ltd
SHE:300679
|
0.050x |
|
National Energy Services Reunited Corp Ordinary Shares
NASDAQ:NESR
|
0.167x |
|
Immunome Inc
NASDAQ:IMNM
|
-0.117x |
Annual Cash Flow Conversion Efficiency for BioCryst Pharmaceuticals Inc (1994–2025)
The table below shows the annual cash flow conversion efficiency of BioCryst Pharmaceuticals Inc from 1994 to 2025. Review BCRX free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-119.15 Million | $329.88 Million | -2.769x | -2632.95% |
| 2024-12-31 | $-475.93 Million | $-52.02 Million | 0.109x | -47.67% |
| 2023-12-31 | $-455.53 Million | $-95.14 Million | 0.209x | -61.98% |
| 2022-12-31 | $-294.60 Million | $-161.85 Million | 0.549x | -58.65% |
| 2021-12-31 | $-106.99 Million | $-142.16 Million | 1.329x | -81.35% |
| 2020-12-31 | $-19.26 Million | $-137.22 Million | 7.124x | +404.18% |
| 2019-12-31 | $38.25 Million | $-89.58 Million | -2.342x | -24.57% |
| 2018-12-31 | $49.23 Million | $-92.56 Million | -1.880x | -282.78% |
| 2017-12-31 | $83.77 Million | $-41.14 Million | -0.491x | +98.55% |
| 2016-12-31 | $1.58 Million | $-53.44 Million | -33.864x | -12221.93% |
| 2015-12-31 | $47.72 Million | $-13.12 Million | -0.275x | +46.08% |
| 2014-12-31 | $75.64 Million | $-38.55 Million | -0.510x | -102.16% |
| 2013-12-31 | $-1.13 Million | $-26.53 Million | 23.561x | -71.40% |
| 2012-12-31 | $-454.00K | $-37.40 Million | 82.372x | +3881.60% |
| 2011-12-31 | $14.81 Million | $-32.25 Million | -2.178x | -408.23% |
| 2010-12-31 | $66.62 Million | $-28.55 Million | -0.429x | -127.97% |
| 2009-12-31 | $86.27 Million | $-16.22 Million | -0.188x | +58.19% |
| 2008-12-31 | $46.43 Million | $-20.87 Million | -0.450x | -16.74% |
| 2007-12-31 | $64.91 Million | $-25.00 Million | -0.385x | +46.44% |
| 2006-12-31 | $21.16 Million | $-15.21 Million | -0.719x | -79.99% |
| 2005-12-31 | $58.44 Million | $-23.35 Million | -0.399x | +35.44% |
| 2004-12-31 | $29.33 Million | $-18.15 Million | -0.619x | -57.22% |
| 2003-12-31 | $28.45 Million | $-11.20 Million | -0.394x | +3.49% |
| 2002-12-31 | $40.13 Million | $-16.36 Million | -0.408x | -128.07% |
| 2001-12-31 | $56.81 Million | $-10.16 Million | -0.179x | -245.95% |
| 2000-12-31 | $61.48 Million | $-3.18 Million | -0.052x | +24.69% |
| 1999-12-31 | $71.40 Million | $-4.90 Million | -0.069x | +54.74% |
| 1998-12-31 | $27.70 Million | $-4.20 Million | -0.152x | +62.76% |
| 1997-12-31 | $25.30 Million | $-10.30 Million | -0.407x | -111.94% |
| 1996-12-31 | $35.40 Million | $-6.80 Million | -0.192x | +71.81% |
| 1995-12-31 | $11.30 Million | $-7.70 Million | -0.681x | -17.41% |
| 1994-12-31 | $11.20 Million | $-6.50 Million | -0.580x | -- |
About BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to… Read more